Abstract
Advanced breast cancer (ABC) remains a significant public health challenge, accounting for the majority of the ∼670,000 breast cancer deaths globally in 2022. In the past decade, significant improvements in survival were seen across all ABC subtypes and patient populations, but disparities remain and ABC continues to be an incurable disease for most people. This manuscript provides an overview of the survival improvements reported for each ABC subtype in clinical trials and in real-world studies since 2015. It highlights where disparities remain and outlines recommendations for the ABC community over the next decade to further improve survival. It summarizes findings from reviews conducted for the ABC Global Alliance's Global Decade Report 2.0. The main findings are: a) Clinical trials showed significant survival gains for ABC in 2015-2025, particularly for hormone receptor-positive and human epidermal growth factor 2 receptor (HER2)-positive subtypes; b) Real-world data mirrors survival trends seen in ABC clinical trials; c) Biomarker-driven treatments offer benefits in ABC, but testing is inconsistent from healthcare professionals; d) Survival disparities remain between ABC subtypes; e) Survival in ABC remains poor compared to early breast cancer. The findings from the ABC Global Alliance's Global Decade Report 2.0 have informed the development of a new ABC Global Charter. The ABC Global Charter 2.0 defines ten new achievable and measurable goals for the decade 2025-2035, aiming at improving the lives of people living with ABC worldwide.